Axcelead has entered into a comprehensive agreement including transfer of key drug discovery platforms with a major Japanese pharmaceutical company

2021.10.18

Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President,　CEO: Yoshinori Ikeura; Axcelead) announces that the company has strengthened the platforms including high-throughput screening (HTS), high-throughput ADME (metabolism & pharmacokinetics) and TOX (safety) studies (HT-ADMET), based on a comprehensive business transfer agreement with a major Japanese pharmaceutical company (hereinafter, referred to as “the pharmaceutical company”).

In recent years, changes in the environment surrounding the pharmaceutical industry have been accelerating, and Japanese and global pharmaceutical companies are working on open innovation activities in various ways. Axcelead has entered into a comprehensive business transfer agreement with the pharmaceutical company to make effective use of the specific drug discovery platforms of the pharmaceutical company and Axcelead’s know-how and experiences in drug discovery research. This comprehensive agreement provides a unique business model as drug discovery role-sharing between a pharmaceutical company and a platform company.　We call this unique model “Horizontal Specialization Model in Drug Discovery”.

A series of enhancements of drug discovery platform in Axcelead would contribute to effective and satisfactorily pipeline construction of customers. The HTS platform by utilizing the 1.5 million compound library offers attractive hit identification service. The HT-ADMET service effectively and quickly provides high-reliable data of various parameters related to physicochemistry, metabolism & pharmacokinetics, and safety.

About Axcelead:

Axcelead is the first comprehensive integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. and started its business in July 2017. Axcelead provides integrated services, from discovery of drug targets to optimization of small- and medium-molecule drug candidates, in which the company has particular expertise, and to the process of bridging the gap to clinical development.

Contacts for Axcelead Drug Discovery Partners, Inc.:
Sales & Marketing
+81-80-7005-5100
E-mail: info@axcelead.com
URL: https://www.axcelead.com/en/